Join us at the American Society of Hematology (ASH)

Join us at the American Society of Hematology (ASH)

Traveling to the American Society of Hematology’s (ASH) annual meeting on December 7–10? We hope to see you at one of our sessions! Save these events to your calendar:

The Max Foundation and iCMLf: Forum for Physicians from Emerging Economic Regions

When & Where:
Friday, December 6, from 12–2 p.m. at the Rosen Plaza Hotel in Orlando, Florida.

Each year, ASH joins thousands of leaders around the world who are working to conquer blood diseases. This is a special opportunity for ASH attendees to share insight and chat with physicians practicing in under-resourced countries.

Download your invitation.

Discussion topics:

  • Perspectives on the future of CML
  • Modeling responses when testing less frequently than monthly
  • Re-evaluating TKI use in pregnancy in 2019

Get to know the speakers: 

Plan on joining?

To reserve your place, please email Arlene Harris-Buchan.

FYI: The Rosen Plaza Hotel is about a 10-minute walk from the Orange County Convention Center.

Patients, Borders, Money, and Mission: A Global Perspective of Chronic Myeloid Leukemia

When & Where:
Two sessions on Saturday, Dec. 7 | 7:30–9 a.m. & 2–3:30 p.m. |Orange County Convention Center, W315, Level 3

Physicians in lower-income countries are facing challenges related to disease diagnosis, optimal management and monitoring, and providing access to treatment for patients with rare blood diseases. As part of ASH Education program, this session will discuss the obstacles of providing services in low-income countries, and how international partnerships are tackling these barriers.

Peek inside the session:

Dr. Scott Ramsey, Director of Hutchinson Institute for Cancer Outcomes at Fred Hutch, will discuss issues related to introducing generic imatinib, costs, and outcomes for patients, and what the implications are for care as second-generation TKIs become available as generics.

Dr. Hemant Malhotra, Professor of Medicine & Head, Division of Medical Oncology at Birla Cancer Center, will focus on disease characteristics in resource-poor countries and the challenges with monitoring CML.

Dr. Jerald Radich, Faculty Member at Fred Hutch, will discuss the problem of BCR-ABL monitoring in areas where a large number of patients have minimal laboratory facilities for RT-PCR testing. He’ll highlight the innovative ways and means for testing and transporting blood samples.

Pat Garcia-Gonzalez, CEO, The Max Foundation, will highlight the challenges when TKIs and basic diagnostics are unavailable for CML patients living in low-income countries. She’ll also discuss the incredible efforts and partnerships The Max Foundation have made to address these issues.

Learn more about this session here.

 

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Welcomes New Board Member, Curt Malloy

    The Max Foundation Welcomes New Board Member, Curt Malloy

    The Max Foundation is pleased to welcome Curt Malloy as the newest member of our Executive Board. Curt, a fellow advocate for people facing cancer around the world, has been a strong supporter of our work for many years throughout his active engagement in global health. Curt currently serves as the Chief Operating Officer at….

  • The Max Foundation Delivers First Treatment into Mozambique

    The Max Foundation Delivers First Treatment into Mozambique

    On November 1, 2019, the first shipment of treatment arrived at the hospital in Maputo, Mozambique. This is the first country Max Access Solutions, The Max Foundation’s patient-centered access model, has expanded into without a former access program in place.

  • The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….